John L Hays, MD, PHD
Academic Title: Associate Professor in the College of Medicine
Research Program: Translational Therapeutics
About Me
More info forI am a medical oncologist who specializes in treating peritoneal cancers stemming from gastrointestinal and gynecological origins, such as ovarian and colorectal cancer, and cancers of the appendix and small intestine. I am an assistant professor in the Department of Internal Medicine at The Ohio State University and a member of the Translational Therapeutics Program at the OSUCCC – James, where my research focuses on using proteomics-based approaches to determine functionally significant signaling nodes within the tumor and its microenvironment using in vitro-based cell culture and co-culture systems. My work has led to the identification of several phosphorylated signaling proteins that are important across multiple ovarian cancer cell lines. My laboratory interests also include understanding the c-MET axis in the tumor microenvironment in ovarian cancer, as well as the biology of mucinous neoplasms of ovarian/appendiceal and colonic origins. I have co-authored a number of articles that have appeared in well-respected publications, such as Journal of Pharmacogenomics and Personalized Medicine, Journal of Biological Chemistry and Journal of Proteomics. I have also shared my work in several presentations to organizations, including the Ovarian Cancer National Alliance. I love being at the OSUCCC – James. I work in the company of first-class physicians, all experts in their respective fields of study. We collaborate on new therapies and treatments for all types of cancer, and together we accomplish so much.
Clinical Expertise
More info for- Stomach Cancers
- Colon Cancers
- Small Intestine Cancer
- Liver Cancers
- Pancreatic Cancers
- Cervical Cancer
- Gynecologic Cancers
- Gallbladder Cancers
- Gastrointestinal Cancers
- Vaginal Cancers
- Rectal Cancers
- Endometrial Cancers
- Ovarian Cancers
- Vulvar Cancers
- Anal Gland Cancer
- Appendix Cancer
- Anal Cancers
- Colorectal Cancers
- Mesothelioma
- Peritoneal Cancers
- Esophageal Cancers
Research Interests
More info for- Neoplasms
- Breast Neoplasms
- Hypersensitivity
- Ovarian Neoplasms
Where I See Patients
More info forEducation & Training
More info forFellowship - Medical Oncology
- National Cancer Institute, NIH
9000 Rockville Pike, Bethesda, MD
Graduate
- University of Texas Medical Branch at Galveston
301 University Blvd, Galveston, TX
Medical School
- University of Texas Medical Branch at Galveston
301 University Blvd, Galveston, TX
Internship - Internal Medicine
- Wake Forest University Baptist Medical Center
1 Medical Center Blvd, Winston Salem, NC
Residency - Internal Medicine
- Wake Forest University Baptist Medical Center
1 Medical Center Blvd, Winston Salem, NC
- National Cancer Institute, NIH
Academic Office & Contact Information
More info forAcademic Office:
Comprehensive Cancer Center
410 W 12th Ave
Columbus, Ohio 43210-1214Email:
hays.161@osu.eduReviews
More info forPatient Satisfaction Review
The overall patient satisfaction rating is an average of all patient responses to the five questions gathered from the Outpatient Oncology survey, developed by Press Ganey Associates for use in oncology clinics across the country. On behalf of The James, Press Ganey administers the survey to patients who see our providers in an outpatient clinic office. For additional information about the patient satisfaction survey, please visit our
Patient Satisfaction Survey page The comments are submitted by patients and reflect their view and opinions. The comments are not endorsed by and do not necessarily reflect the views of The James.
Videos
More info forPublications
More info forAugust 20, 2024Mature MUC5AC Expression in Resected Pancreatic Ductal Adenocarcinoma Predicts Treatment Response and Outcomes.
Manne A, Esnakula A, Sheel A, Sara A, Manne U, Paluri RK, He K, Yang W, Sohal D, Kasi A, Noonan AM, Mittra A, Hays J, Roychowdhury S, Malalur P, Rahman S, Jin N, Cloyd JM, Tsai S, Ejaz A, Pitter K, Miller E, Thanikachalam K, Dillhoff M, Yu L
Int J Mol Sci
June 20, 2024Use of non-steroidal anti-inflammatory drugs and pancreatic cancer risk in the Women's Health Initiative.
Brasky TM, Jager LR, Newton AM, Li X, Loomans-Kropp HA, Hays JL, Margolis KL, Luo J
Cancer Epidemiol Biomarkers Prev
January 18, 2024Current cannabis use and pain management among US cancer patients.
Krok-Schoen JL, Plascak JJ, Newton AM, Strassels SA, Adib A, Adley NC, Hays JL, Wagener TL, Stevens EE, Brasky TM
Support Care Cancer
January 1, 2024Testing the feasibility of mobile ecological momentary assessment for symptom burden and management among metastatic cancer patients.
Brasky TM, Newton AM, Stephens JA, Strassels SA, Benzo RM, Hays JL, Stevens E, Wagener TL, Hedeker D, Krok-Schoen JL
Digit Health
December 29, 2023Associations of Cancer Patients' Demographic and Clinical Characteristics With Cannabis-Related Interest and Behaviors.
Adley NC, Brasky TM, Conroy SR, Newton AM, Plascak JJ, Strassels SA, Hays JL, Krok-Schoen JL
J Palliat Med
September 22, 2023Marijuana and Cannabidiol Use Prevalence and Symptom Management Among Patients with Cancer.
Brasky TM, Newton AM, Conroy S, Adib A, Adley NC, Strassels SA, Hays JL, Cooper ZD, Wagener TL, Stevens E, Plascak JJ, Krok-Schoen JL
Cancer Res Commun
June 19, 2023ARTISTRY-7: Phase III trial of nemvaleukin alfa plus pembrolizumab vs chemotherapy for platinum-resistant ovarian cancer.
Herzog TJ, Hays JL, Barlin JN, Buscema J, Cloven NG, Kong LR, Tyagi NK, Lanneau GS, Long BJ, Marsh RL, Seward SM, Starks DC, Welch S, Moore KN, Konstantinopoulos PA, Gilbert L, Monk BJ, O'Malley DM, Chen X, Dalal R, Coleman RL, Sehouli J
Future Oncol
March 9, 2023Supplemental B-Vitamins and Risk of Upper Gastrointestinal Cancers in the Women's Health Initiative.
Brasky TM, Ray RM, Newton AM, Navarro SL, Schenk JM, Loomans-Kropp HA, Arthur RS, Snetselaar LG, Hays J, Neuhouser ML
Nutr Cancer
July 14, 2022Randomized, Double-Blind, Placebo-Controlled Phase III Study of Paclitaxel ± Napabucasin in Pretreated Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.
Shah MA, Shitara K, Lordick F, Bang YJ, Tebbutt NC, Metges JP, Muro K, Lee KW, Shen L, Tjulandin S, Hays JL, Starling N, Xu RH, Sturtz K, Fontaine M, Oh C, Brooks EM, Xu B, Li W, Li CJ, Borodyansky L, Van Cutsem E
Clin Cancer Res
May 26, 2022Randomized, double-blind, placebo-controlled phase 3 study of paclitaxel {plus minus} napabucasin in pretreated advanced gastric or gastroesophageal junction adenocarcinoma.
Shah MA, Shitara K, Lordick F, Bang YJ, Tebbutt NC, Metges JP, Muro K, Lee KW, Shen L, Tjulandin S, Hays JL, Starling N, Xu RH, Sturtz K, Fontaine M, Oh C, Brooks E, Xu B, Li W, Li CJ, Borodyansky L, Van Cutsem E
Clin Cancer Res
April 25, 2022Drivers of genomic loss of heterozygosity in leiomyosarcoma are distinct from carcinomas.
Seligson ND, Tang J, Jin DX, Bennett MP, Elvin JA, Graim K, Hays JL, Millis SZ, Miles WO, Chen JL
NPJ Precis Oncol
February 23, 2022The siren's song of anonymous web-based sampling.
Brasky TM, Krok-Schoen JL, Conroy S, Newton AM, Strassels SA, Hays JL, Wagener TL
Cancer
February 1, 2022Clinical Utility of CDK4/6 Inhibitors in Sarcoma: Successes and Future Challenges.
Hsu JY, Seligson ND, Hays JL, Miles WO, Chen JL
JCO Precis Oncol
August 19, 2021RaPiDS (GOG-3028): randomized Phase II study of balstilimab alone or in combination with zalifrelimab in cervical cancer.
O'Malley DM, Randall LM, Jackson CG, Coleman RL, Hays JL, Moore KN, Naumann RW, Rocconi RP, Slomovitz BM, Tewari KS, Ancukiewicz M, Feliu WO, Monk BJ
Future Oncol
July 13, 2021Phase I evaluation of lenvatinib and weekly paclitaxel in patients with recurrent endometrial, ovarian, fallopian tube, or primary peritoneal Cancer.
Backes FJ, Wei L, Chen M, Hill K, Dzwigalski K, Poi M, Phelps M, Salani R, Copeland LJ, Fowler JM, Cohn DE, Bixel K, Cosgrove C, Hays J, O'Malley D
Gynecol Oncol
May 21, 2021Multiscale-omic assessment of EWSR1-NFATc2 fusion positive sarcomas identifies the mTOR pathway as a potential therapeutic target.
Seligson ND, Maradiaga RD, Stets CM, Katzenstein HM, Millis SZ, Rogers A, Hays JL, Chen JL
NPJ Precis Oncol
March 2, 2021CD4 T cell dependent rejection of beta 2 microglobulin null mismatch repair deficient tumors.
Germano G, Lu S, Rospo G, Lamba S, Rousseau B, Fanelli S, Stenech D, Le DT, Hays J, Totaro MG, Amodio V, Chila R, Mondino A, Diaz LA, Di Nicolantonio F, Bardelli A
Cancer Discov
February 17, 2021Post hoc analyses of GOG 9923: Does BRCA status affect toxicities?: An NRG oncology study.
Gillen J, Miller A, Bell-McGuinn KM, Schilder RJ, Walker JL, Mathews CA, Duska LR, Guntupalli SR, O'Cearbhaill R, Hays J, Hagemann AR, Gray HJ, Gordon SW, Armstrong DK, Chen A, Fracasso PM, Aghajanian C, Moore KN
Gynecol Oncol
October 23, 2020Phase 1 study of the HSP90 inhibitor onalespib in combination with AT7519, a pan-CDK inhibitor, in patients with advanced solid tumors.
Do KT, O'Sullivan Coyne G, Hays JL, Supko JG, Liu SV, Beebe K, Neckers L, Trepel JB, Lee MJ, Smyth T, Gannon C, Hedglin J, Muzikansky A, Campos S, Lyons J, Ivy P, Doroshow JH, Chen AP, Shapiro GI
Cancer Chemother Pharmacol
August 17, 2020The Role of Hyperthermic Intraperitoneal Chemotherapy for Non-colorectal Peritoneal Surface Malignancies.
Morris MC, Cloyd JM, Hays J, Patel SH
J Gastrointest Surg
August 5, 2020Practice patterns in post-treatment surveillance in patients with primary epithelial ovarian cancer.
DeMari J, Vetter MH, Chandra S, Hays JL, Salani R
Int J Gynecol Cancer
August 4, 2020MDM2-Dependent Rewiring of Metabolomic and Lipidomic Profiles in Dedifferentiated Liposarcoma Models.
Patt A, Demoret B, Stets C, Bill KL, Smith P, Vijay A, Patterson A, Hays J, Hoang M, Chen JL, Mathé EA
Cancers (Basel)
July 31, 2020Phase II trial of bevacizumab and sorafenib in recurrent ovarian cancer patients with or without prior-bevacizumab treatment.
Lee JM, Annunziata CM, Hays JL, Cao L, Choyke P, Yu M, An D, Turkbey IB, Minasian LM, Steinberg SM, Chen H, Wright J, Kohn EC
Gynecol Oncol
May 7, 2020Outcomes of neoadjuvant chemotherapy before CRS-HIPEC for patients with appendiceal cancer.
Chen JC, Beal EW, Hays J, Pawlik TM, Abdel-Misih S, Cloyd JM
J Surg Oncol
Consulting and Related Relationships
More info forAt The Ohio State University Wexner Medical Center, we support a faculty member’s research and consulting in collaboration with medical device, research and/or drug companies because a faculty member’s expertise can guide important advancements in the practice of medicine and improve patient care. In order to provide effective management of these relationships, the university requires annual disclosures from all faculty members with external interests related to their university responsibilities. As of 09/30/2024, Dr. Hays has reported relationships with the companies or entities listed below. If you have questions about the relationships listed below, please ask the faculty member. If you have questions about how these relationships are monitored by The Ohio State University Wexner Medical Center, please contact our Compliance Office.
- AstraZeneca
- GOG Foundation, Inc.
- Curio Science LLC
- Mersana Therapeutics
- MJH LIfe Sciences
- Alkermes, Inc.
- Merck Sharp & Dohme
Patient Comments
If the university requires doctors to see more patients daily then the time they spend with each patient will suffer. Dr. Hays always spends time going over plans and discusses wellness plans. He is a wonderful doctor that follows up quickly and addresses questions thoroughly.
Dr. Hayes is very proficient in my rare cancer.
Dr. Hayes takes the time to give options and listens to my concerns.
Dr. Hays is an excellent Oncologist. He really cares about his patients.
Dr Hayes listen to me and tell me what's the best way to handle my issue if any
Dr Hays is amazing!!
Dr. John Hays gave me all the time I needed, fully answered all of my questions nd concerns. Thank you
Dr. Hayes was very up front and explained every thing we ask bout.
The very best doctor. NP, nurses and staff
Dr. Hays never rushed you, answers any & all questions, clarifies everything & gives the best hugs.
Dr. Hays is very warm, engaging and informative. He speaks candidly at my request and I have complete trust in him for my continued care, even though this visit involved cancer recurrence, common for my condition as I understand it.
Dr. Hays & his team are awesome. Very caring. Excellent doctor!
Dr. Hays is always welcoming and friendly. Willing to listen to my concern.
Doctor Hays is absolutely wonderful to talk to, we are so thankful for him. He never makes us feel rushed and answers all our questions.